TCT 2012 UPDATE: St. Jude Medical ticks up on positive PressureWire data

October 24, 2012 By MassDevice staff

Results from the Fame II study comparing St. Jude Medical‘s (NYSE:STJ) PressureWire fractional flow reserve device with optimal medical care show that FFR-guided coronary interventions are more cost-effective, sending STJ shares up nearly 2% today on Wall Street.

The St. Paul, Minn.-based medical device company funded the trial, which earlier this year demonstrated that the FFR-guided PCI arm patients fared better than the control arm. Now the company said the data also show that the procedure is less expensive than medical therapy alone over the long term.

Dr. William Fearon of Stanford University, presenting data at the Transcatheter Cardiovascular Therapeutics conference today in Miami, said that the previous Courage trial influences cardiologists to let optimal medical therapy run its course before attempting PCI, according to heartwire.

"Based on Courage, people have argued that up-front optimal medical therapy should be achieved before proceeding to PCI, but what we showed in FAME II was that if you can identify ischemia-producing lesions and isolate those, patients [with those lesions] benefit from PCI up front as compared with optimal medical therapy, by decreasing urgent revascularization and improving quality of life," Fearon said, according to the website.

During the 1st year, optimal medical therapy costs about $2,508 less than FFR-guided PCI. But reduced incidence of angina and urgent revascularization make FFR-guided PCI more cost-effective over time. Angiography-guided PCI posted a cost-effectiveness ratio of $168,000 per quality-adjusted life-year; for FFR-guided PCI in Fame II, that number was $53,000 – comparable to other widely accepted therapies, Fearon said.

"We want to be conservative and not overstate things," he said, according to heartwire. "We don’t have longer follow-up at this time, but … the benefit of PCI lasted more than 1 year in Courage, and freedom from angina [in the PCI group] lasted out to 3 years."

"While FFR-guided PCI had a higher initial cost than patients treated by medical therapy alone, after 1 year the cost gap narrowed by more than 50% due to a higher number of hospital re-admissions for patients treated only with medical therapy," St. Jude Medical said in a press release.

The news sent STJ shares up 1.6% to a $39.71 close today. Shares were up slightly at $39.73 in after-hours trading.

Early this year, St. Jude cut short the Fame II study due after an interim analysis showed that 11.1% of the optimal-medical-management arm needed urgent revascularization, compared with 1.6% of the PCI cohort, according to heartwire.

The shortened duration of the study poses a problem for skeptics including Dr. William Boden, who wrote an editorial for the New England Journal of Medicine, "What is More Enduring – Fame or Courage?," questioning the study’s validity due to its shortened term.

"Clearly, FFR holds potential promise for a more targeted approach to PCI that might be more clinically effective and cost-effective than visually directed PCI for all angiographically significant stenoses," Boden wrote. "Unfortunately, the early termination of the FAME II trial before full enrollment and follow-up were achieved, the neutral effects on the rate of death or myocardial infarction, and the lack of a significant, sustained treatment effect on the reduction of angina beyond 6 months leave more questions than answers."

The Fame II study proved to be important, not just for St. Jude, but for FFR rival Volcano Corp. (NSDQ:VOLC). Those companies are embroiled in a bitter patent dispute over FFR technology. The study could also help boost the sagging stents businesses of the major players in the market, Boston Scientific (NYSE:BSX), Abbott (NYSE:ABT) and Medtronic (NYSE:MDT).

What’s next for nitinol tubing?
Nitinol’s unique properties have made it the darling of the medical device industry. A novel technique for mechanically joining nitinol to other metal tubing could reduce cost and mitigate risk. Mark Broadley, Viant Nitinol has revolutionized the medical device industry. With its flexible superelasticity, shape memory and biocompatibility, nitinol has become a go-to material for… […]
Report: Haemonetics’ blood-collection devices could leave particles in donors
A consortium of news outlets is questioning the safety of Haemonetics (NYSE:HAE) blood-collection devices, claiming that particles have been detected in donors whose plasma was extracted by the machines. According to a report in the Miami Herald, whistleblower documents indicate that more than 150 Haemonetics customer reports have been made regarding the presence of particles by plasma collection centers and heathcare… […]
Spinal Elements’ cervical fixation system wins FDA nod
Spine surgery technology developer Spinal Elements announced today that it received FDA clearance for its Sapphire X product for anterior cervical fixation. Sapphire X is comprised of integrated instrumentation and high-angulation screws designed to help surgeons perform a procedure while preserving the patient’s skeletal and muscle tissue. The instrumentation is designed to reduce procedural steps… […]
How COVID-19 impacts FDA interactions with medical device manufacturers
By Stewart Eisenhart, Emergo Group The US Food and Drug Administration may revise performance goals and timelines set under the Medical Device User Fee Amendments IV (MDUFA IV) as emergency efforts targeting the coronavirus pandemic take up more of the agency’s time. Get the full story here at the Emergo Group’s blog. The opinions expressed… […]
Switchback Medical adds ‘sandbox approach’ to device testing
Contract manufacturer Switchback Medical (Maple Grove, Minn.) today announced that it has added a new division. Switchback BioSim Innovations offers functional dynamic biosimulator model development, cell culture services and physician training, according to the company. Biosimulator models use animal and human tissue to create functional models, such as a pumping heart with working valves to… […]
Smith College team wins ventilator design challenge
A team of Smith College engineering alumnae, staff and faculty has won the CoVent-19 Challenge to design a rapidly deployable ventilator to address shortages caused by the COVID-19 pandemic, particularly in developing countries. A dozen anesthesiology resident physicians from Massachusetts General Hospital kicked off the public challenge April 1, attracting 200 entries. The 30-person team… […]
FDA gives certain device makers more time to add UDIs
The FDA said today that it will grant manufacturers of Class 1 and unclassified medical devices and certain others more time to add unique device identifiers (UDIs) to their products. These companies will now have until Sept. 24, 2022 to comply with the agency’s UDI rule, including standard date formatting, labeling and Global Unique Device… […]
Eurofins launches 10-minute COVID-19 exposure testing device
Eurofins (Paris:ERF.PA) announced today that it launched its rapid point-of-care testing devices to identify past exposure to COVID-19. The serology-based, finger-prick tests detect antibodies with a sensitivity of 94.5% from 19 days following the onset of symptoms, with results coming in just 10 minutes, according to a news release. Get the full story at our sister site,… […]
How is RF technology shaping the future of medtech?
RF technology, including microwaves, isn’t just about wireless communications or military radar these days. Times Microwave Systems experts point out that it is increasingly important when it comes to medtech. Many medical electronics systems such as magnetic resonance imaging (MRI) systems for cancer detection rely on RF/microwave technology. Times Microwave Systems (Wallingford, Conn.) is hosting… […]
Medical device litigation and COVID-19: What you need to know
The COVID-19 pandemic is creating a new set of medical device litigation challenges — but also a chance for an industry reset. One of Greenberg Traurig’s top medtech litigation lawyers shares her insights. Sara Thompson doesn’t take any guff when she tells people that she defends medical device and pharmaceutical companies from lawsuits. “I say,… […]
Mayo Clinic needed to engineer its way through COVID-19: Here’s what they did.
The health system’s medical and engineering staffs had to devise their own solutions for lab gear, PPE and operating room air decontamination. As COVID-19 settles into several regions of the U.S., healthcare systems that once sat on the sidelines likely will find themselves in the same situation as their counterparts in the Northeast did earlier… […]